Clinigen

Clinigen

Global pharmaceutical services and medicine access

Overview

Clinigen provides pharmaceutical services and medicines to help patients access treatments. It revitalizes niche, hospital-only medicines and offers end-to-end services across the product lifecycle through three divisions: Clinical Services, Access and Commercialisation, and Lifecycle Services. The company supports pharma partners with clinical trial supply, managed access programs for unlicensed medicines, market access, and regulatory affairs, distributing products in 100+ countries. Its goal is to ensure ethical patient access by combining product revival with comprehensive lifecycle management on a global scale.

About Clinigen

Simplify's Rating
Why Clinigen is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Consulting

Healthcare

Company Size

501-1,000

Company Stage

IPO

Headquarters

Branston, United Kingdom

Founded

2010

Get referred to Clinigen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PreemieFort approval in Japan opens a new regulated market and premium neonatal channel.
  • Shionogi's cefiderocol deal in Australia and New Zealand expands access and royalties.
  • Clinigen now serves 1,000-plus pharma partners globally, strengthening recurring service demand.

What critics are saying

  • Fitch kept Clinigen at B with negative outlook on 5 June 2025, pressuring refinancing.
  • Erwinase production ended in 2025; shortages run through February 2026, threatening access revenue.
  • The business depends on a few niche medicines; one supply failure can cascade quickly.

What makes Clinigen unique

  • Clinigen secured Japan's first prescription-drug approval for human milk fortifier on 12 February 2026.
  • SSI Strategy acquisition closed 21 November 2025, adding 200-plus consultants and biotech advisory depth.
  • Greg Skalicky's 20 July 2026 appointment brings Eversana commercialisation expertise to Clinigen.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$66M

Above

Industry Average

Funded Over

2 Rounds

Buyout funding comparison data is currently unavailable. We're working to provide this information soon!
Buyout Funding Comparison
Coming Soon

Benefits

Paid Vacation

Performance Bonus

Professional Development Budget

Training Programs

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
ConnectWeb
Jul 20th, 2026
News & articles.

News & articles. At ConnectWeb Connectweb has a team of editors and researchers collating the most relevant information to you and your industry. All Directories' publications and sites provide a wealth of information for research or marketing, and are used by public and corporate libraries, educational institutions, government departments, corporations and SMEs across the country. You are here: Home News Access the latest company news and announcements distributed through Medianet. Technology & Innovation 20/07/2026 21:18 Clinigen appoints Greg Skalicky as Chief Executive Officer. LONDON-BUSINESS WIRE- Clinigen, the global pharmaceutical services company dedicated to accelerating access to critical medicines worldwide, today announced the appointment of Greg Skalicky as Group Chief Executive Officer, effective 20 July 2026. Greg succeeds Dr Varun Sethi, who has served as Acting CEO since September 2025. Skalicky brings more than 30 years of leadership experience, with a unique blend of clinical and commercial expertise in the pharmaceutical, biotechnology and healthcare sectors. He joins Clinigen following a distinguished career leading large-scale organisations, with a track record of driving growth, global expansion, and transformative partnership structures. Most recently he served as President of Eversana, where he designed and implemented the industry's first fully integrated commercialisation model. Prior to Eversana, he held senior leadership roles at Syneos Health (formerly inVentiv Health) and PharmaNet, managing major global client relationships with leading pharmaceutical companies. As Group CEO, Skalicky will lead Clinigen through its next phase of growth, building on the company's strong position as a trusted partner to pharmaceutical and biotechnology companies across clinical trial services, strategic staffing and global compassionate use programs. "Greg is an accomplished healthcare executive with deep industry expertise and a proven ability to scale global organisations," said Paul Carter, Chairman of Clinigen. "His extensive experience across commercialisation, patient access, and pharmaceutical services makes him exceptionally well positioned to lead Clinigen into its next chapter. Our ambition is to offer pharma and biotech clients a fully integrated partner to deliver access to critical medicines across the pharmaceutical lifecycle, and Greg's experience positions him perfectly to deliver on that vision. I would like to thank Varun for his outstanding leadership as Acting CEO, during which time he has continued to strengthen the business and advance our strategic priorities." "I am honoured to join Clinigen at such an exciting time in the company's evolution," said Greg Skalicky. "Clinigen has built an outstanding reputation for solving some of the most complex access and supply challenges in healthcare. The company's mission, expertise, and commitment to patients deeply resonate with me. I look forward to working alongside our talented global team to accelerate growth, enhance client value, and expand access to critical medicines for patients around the world." Clinigen serves more than 1,000 pharmaceutical and biotechnology partners globally and operates across five continents. Under Skalicky's leadership, the company will continue to focus on operational excellence, customer partnership, innovation, and strategic expansion. About Clinigen Clinigen is a global pharmaceutical services company trusted by pharmaceutical and biotechnology organisations worldwide. With decades of experience, Clinigen helps accelerate access to critical medicines across the product lifecycle. Headquartered in the UK with operations across Europe, the Americas, and Asia-Pacific, Clinigen's purpose is to be the global pathfinder accelerating patient access to critical medicines. Clinigen was acquired by Triton Partners in April 2022. Contact details: For further information, please contact: Julian Tyndale-Biscoe (UK)- [email protected] Carrie Young (US)- [email protected] Aanchal Agarwal (APAC)- [email protected] * images - clinigenlogo.jpg download. ConnectWeb. ConnectWeb is Australia's leading publisher of biographical data, directories and specialist newsletters. With ConnectWeb you gain access to its comprehensive database of contacts and companies in media, government and associations. Connect with Connectweb.

Yahoo Finance
Jul 20th, 2026
Clinigen names Greg Skalicky as CEO to lead pharmaceutical services expansion

Clinigen, a global pharmaceutical services company, has appointed Greg Skalicky as group chief executive officer, effective 20 July 2026. He succeeds Dr Varun Sethi, who served as acting CEO since September 2025. Skalicky brings over 30 years of leadership experience in pharmaceutical, biotechnology, and healthcare sectors. Most recently, he served as president of Eversana, where he designed the industry's first fully integrated commercialisation model. Previously, he held senior roles at Syneos Health and PharmaNet. As group CEO, Skalicky will lead Clinigen's growth, building on its position across clinical trial services, strategic staffing, and global compassionate use programmes. Chairman Paul Carter praised Skalicky's expertise in commercialisation, patient access, and pharmaceutical services, noting his ability to scale global organisations.

PR Newswire
Feb 12th, 2026
Clinigen secures world-first pharmaceutical approval for human milk-based fortifier in Japan

Clinigen has secured world-first pharmaceutical approval in Japan for Prolacta Bioscience's PreemieFort Enteral Solution, a human milk-based fortifier. The product is indicated for nutritional management of very low birth weight infants and neonates with weight gain failure. Whilst regulated as infant formula in the US and Europe, PreemieFort became the first human milk-derived product approved as a prescription drug in Japan. The approval was supported by data from the JASMINE Phase III clinical trial in very low birth weight infants. Clinigen served as exclusive licensee and marketing authorisation holder, working with regulators to establish a pharmaceutical pathway where none previously existed. The achievement is particularly significant given Japan's rigorous regulatory standards and status as a global leader in neonatal care.

Clinigence Group
Jan 2nd, 2026
Acquisition of CSM for initial consideration of $150 million | Clinigen

Acquisition of CSM for initial consideration of $150 million

Investors in Healthcare
Sep 29th, 2025
UK: Triton-backed Clinigen acquires SSI Strategy from Amulet Capital

UK: triton-backed Clinigen acquires SSI Strategy from Amulet Capital.

Recently Posted Jobs

Sign up to get curated job recommendations

Clinigen is Hiring for 13 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →